Key result
Microaxial flow pump ≤6 hours linked to ~75% lower in-hospital mortality in STEMI.
Why the study?
The association between microaxial flow pump timing and outcomes in acute myocardial infarction-related cardiogenic shock remains uncertain.
Does microaxial flow pump implantation within 6 hours reduce subsequent in-hospital mortality in patients with STEMI-related cardiogenic shock who survive the first 24 hours of ICU admission?
Cohort (n=165)
No
Does microaxial flow pump implantation within 6 hours reduce subsequent in-hospital mortality in patients with STEMI-related cardiogenic shock who survive the first 24 hours of ICU admission?
Odds Ratio: 0.25 (95% CI 0.06–0.99)
Absolute Event Rate: 17% vs 23.7%
p-value: p=0.048
In patients with STEMI-related cardiogenic shock surviving the first 24 hours, early implantation of a microaxial flow pump within 6 hours may be associated with reduced in-hospital mortality compared to medical management alone.
Should not alter mAFP timing decisions in AMI-CS yet; leaves open optimal strategies for randomized evaluation.
(1) Background: The association between microaxial flow pump (mAFP) timing and outcomes in acute myocardial infarction-related cardiogenic shock (AMI-CS) remains uncertain. (2) Methods: We conducted a retrospective single-center study of patients with AMI-CS admitted between January 2017 and July 2025. Prespecified 24 h landmark analyses included patients alive 24 h after intensive care unit (ICU) admission. The primary analysis compared patients with ST-segment elevation myocardial infarction (STEMI) receiving mAFP within 6 h with STEMI patients managed without temporary mechanical circulatory support (tMCS). Later STEMI implantation (>6–≤24 h) and both non-ST-segment elevation myocardial infarction (NSTEMI) timing cohorts were exploratory. The primary endpoint was subsequent in-hospital mortality from the landmark onward. Associations were assessed using multivariable logistic regression and propensity score-weighted models. (3) Results: In the primary STEMI cohort, 106 patients received mAFP within 6 h and 59 received no-tMCS. Subsequeunt in-hospital mortality was 17.0% versus 23.7%, respectively (p = 0.293). Early mAFP implantation was associated with lower mortality in the fully adjusted model (OR, 0.25 [95% CI, 0.06–0.99]; p = 0.048). Propensity score-based estimates were directionally consistent, with significance in the doubly robust weighted model (OR, 0.22 [95% CI, 0.06–0.85]; p = 0.028) but not in all weighted models. Later-timing and NSTEMI estimates did not reach statistical significance and were imprecise. (4) Conclusions: Among patients with STEMI who survived the first 24 h after ICU admission, mAFP implantation within 6 h was associated with lower subsequent in-hospital mortality. Exploratory later-timing and NSTEMI estimates were inconclusive. These observational findings are hypothesis-generating and require prospective validation.
No takes yet. Share an insight, caveat, or question.
Mihali et al. (2026) conducted a cohort in Acute myocardial infarction-related cardiogenic shock (AMI-CS) (n=165). Microaxial flow pump (mAFP) within 6 hours vs. No temporary mechanical circulatory support (tMCS) was evaluated on Subsequent in-hospital mortality from the 24 h landmark onward (OR 0.25, 95% CI 0.06-0.99, p=0.048). Microaxial flow pump implantation ≤6 hours was associated with lower in-hospital mortality vs no support in STEMI patients surviving 24 hours (OR 0.25; 95% CI 0.06-0.99; P=0.048).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: